Immunic (NASDAQ:IMUX) Upgraded by StockNews.com to "Hold" Rating

StockNews.com upgraded shares of Immunic (NASDAQ:IMUX - Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday morning.

Several other research analysts have also commented on the stock. D. Boral Capital restated a "buy" rating and set a $17.00 price target on shares of Immunic in a research note on Tuesday, January 7th. HC Wainwright started coverage on Immunic in a report on Monday, November 25th. They set a "buy" rating and a $10.00 target price on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Immunic presently has a consensus rating of "Buy" and a consensus price target of $12.67.

Immunic Price Performance

Immunic stock traded down $0.02 during mid-day trading on Friday, hitting $0.95. The company's stock had a trading volume of 513,490 shares, compared to its average volume of 1,087,404. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11. The company has a market cap of $85.58 million, a PE ratio of -0.77 and a beta of 1.87. The firm's 50 day moving average is $1.08 and its 200 day moving average is $1.29.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). During the same quarter last year, the firm posted ($0.51) EPS. As a group, analysts forecast that Immunic will post -0.94 EPS for the current year.

Insider Transactions at Immunic

In other news, Director Richard Alan Rudick bought 87,300 shares of the company's stock in a transaction dated Tuesday, November 12th. The stock was bought at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the transaction, the director now directly owns 87,300 shares in the company, valued at $100,395. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Immunic

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. HB Wealth Management LLC bought a new stake in shares of Immunic during the fourth quarter worth $81,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock worth $169,000 after purchasing an additional 42,383 shares during the period. Jane Street Group LLC increased its holdings in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after purchasing an additional 38,553 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Immunic in the 3rd quarter valued at about $50,000. Finally, State Street Corp boosted its position in shares of Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after buying an additional 11,642 shares during the period. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.